TELIX PHARMACEUTICALS LTD (TLX.AU) stock soared 5.59% during intraday trading on Friday, reflecting strong investor sentiment.
The surge follows the company's release of its full-year revenue results and forward guidance. Telix reported FY revenue of US$803.8 million and provided FY 2026 group revenue guidance of US$950 million to US$970 million, indicating robust expected growth. Additionally, the company reported a non-material loss before tax of US$5.3 million for the period.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.